Document is current
Any future updates will be listed below
-
Authors
Rybalka, Emma https://orcid.org/0000-0002-4854-0036
Park, Hyung Jun
Nalini, Atchayaram
Baskar, Dipti
Polavarapu, Kiran
Durmus, Hacer
Xia, Yang
Wan, Linlin
Shieh, Perry B.
Moghadaszadeh, Behzad
Beggs, Alan H.
Mack, David L.
Smith, Alec S. T.
Hanna-Rose, Wendy
Jinnah, Hyder A.
Timpani, Cara A.
Shen, Min
Upadhyay, Jaymin
Brault, Jeffrey J.
Hall, Matthew D.
Baweja, Naveen
Kakkar, Priyanka
- License Information
-
More Information
Article History
Received: 27 July 2024
Accepted: 24 October 2024
First Online: 26 November 2024
Declarations
:
: Human and animal studies were approved by the relevant institutional ethics boards and informed consent was given by all human participants.
: Not applicable.
: ER has received consulting income from Santhera Pharmaceutical and Epirium Bio. PBS has received personal compensation from Novartis Gene Therapies Inc., Alexion argenyx, Biogen, Catalyst, Grifols, CSL Behring, Genentech, Pfizer, PTC Therapeutics, and Sarepta Therapeutics; research funding from Astellas Gene Therapies, Biogen, Catalyst, Pfizer, PTC, Sanofi-Genzyme, Sarepta, Solid Biosciences, and Zogenix. DM founded Kinea Bio Inc., is on the scientific advisory board of Curi Bio Inc., Vita Therapeutics Inc., and SoundEats Inc., and receives consulting income from Astellas Gene Therapies. AHB receives consulting income from Kate Therapeutics, Roche Pharmaceuticals, GLG Inc., and Guidepoint Global, and has equity in Kate Therapeutics and Kinea Bio. All other authors declare no competing interests.
